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Abstract
The purpose of this study was to examine the frequencies and structure of score on Minimum 
Data Set 2.0 (MDS 2.0) items relevant to disruptive behaviour and antipsychotic medications in 
Ontario LTC home residents. These items consisted of delirium, restraint use, activities of daily 
living (ADLs), depression, cognitive impairment and bladder incontinence. Lisrel Path analysis 
was used for the analysis. Significant positive effects were found between delirium and 
disruptive behaviour, cognitive impairment and delirium, disruptive behaviour and antipsychotic 
medication, depression and disruptive behaviour, depression and delirium, restraint use and 
delirium, cognitive impairment and antipsychotic medication, ADLs and antipsychotic 
medication, ADLs and restraint use, cognitive impairment and restraint use. Significant negative 
effects were found between antipsychotic medication and disruptive behaviour, ADLs and 
antipsychotic medication, and disruptive behaviour and delirium.
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Literature Review
The Behavioural and Psychological Symptoms of Dementia (BPSD) include behavioural 
symptoms, psychotic symptoms, mood symptoms and other symptoms such as diurnal rhythm 
disturbance that can affect elderly patients with dementia. These behaviours are very frequent 
and occur in as many as 90% of patients with dementia. Causes are not well understood although 
biochemical, neuroanatomical, and personality traits have been associated with BPSD. Some 
researchers found a link between delirium, depression, bladder incontinence and disturbing 
behaviour in long-term care facilities for the elderly. It is important to pinpoint these conditions 
and deal with them appropriately.
For the most part, these disruptive behavioural symptoms are managed with psychotropic 
medications. Their use is controversial, however, because many controlled studies continue to 
raise questions as to their effectiveness and their side effects are numerous and dangerous. 
Between 2002 and 2004, Health Canada, the FDA, and the U.K. Committee of Safety of 
Medicine issued advice and warnings to physician regarding the increased risk of death and 
increased risk of cerebrovascular events in elderly patients with dementia treated with 
antipsychotics. All prescribing information now indicates that antipsychotic medications are not 
recommended for elderly patients with dementia.
Despite these warnings, however, antipsychotic drugs continue to be prescribed at an 
alarming rate, especially for those elderly confined to long-term care facilities.
Although this review of the literature mainly pertains to the behavioral and psychological 
symptoms of dementia (BPSD), these symptoms are not exclusively seen in patients diagnosed 
with dementia.
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Types o f Dementia
Dementia includes a loss of brain function. It is not a single disease but encompasses a 
group of illnesses that involve memory, behaviour, learning and communication problems. These 
problems are progressive. Alzheimer’s disease (AD) is the most common cause of dementia. 
(Bums & DeDeyn, 2006). It is characterized by dense accumulation of neurofibrillary tangles 
and amyloid plaques in the medial temporal lobe and leads to neuronal loss that is visible as 
atrophy on MRIs. A 6-year longitudinal cohort study found that atrophy of the hippocampus and 
amygdala also predicted dementia in cognitively intact elderly people (Heijer et al., 2006). The 
other major cause of nonreversible dementia is vascular dementia which is caused by a series of 
small strokes. These two conditions often co-occur.
Another type of dementia is called Dementia with Lewy Bodies (DLB). DLB is linked to 
abnormal protein structures in the brain. It is associated with AD but it is not known if DLB is a 
subtype of AD or a separate disease. Also associated with dementia-like symptoms are damaged 
blood vessels or nerve structures, and conditions such as Parkinson’s disease, progressive 
supranuclear palsy (Steele-Richardson-Olszewski syndrome), Creutzfeldt-Jakob disease, 
cerebrovascular disease, central nervous system infection, brain trauma or tumours, vitamin 
deficiencies, anoxia, metabolic conditions, endocrine conditions, immune disorders. Prion 
disease, Wemicke-Korsakoff syndrome, normal-pressure Hydrocephalus, Huntington’s chorea, 
AIDS and multiple sclerosis.
Diagnostic features include multiple cognitive deficits that include memory impairment 
and at least one of these cognitive disturbances: aphasia, apraxia, agnosia, or a disturbance in 
executive functioning. Persons with dementia have difficulty learning new material, or may 
forget previously learned material. Both forms of memory impairment are usually seen in people
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with dementia. They may have difficulty naming individuals and objects (aphasia). Apraxia may 
manifest as the inability to comb their hair or wave goodbye. In the later stage they will become 
unable to recognize family members or even their own reflection in the mirror. Disturbances in 
executive functioning which involve the ability to think abstractly and to plan, initiate, sequence, 
monitor, and stop complex behaviour are common. The individual may have difficulty coping 
with new tasks and may avoid situations that involve the learning of new and complex 
information. These criteria must be severe enough to cause significant impairment in social and 
occupational functioning and must represent a decline from a previous level of functioning. 
Dementia is not diagnosed if these symptoms occur exclusively during the course of a delirium 
(American Psychiatric Association, 2000).
Behavioural and Psychological Symptoms o f Dementia
The BPSD are not newly discovered phenomena. Over a century ago they were described 
by Alois Alzheimer who in his case description of the illness (Alzheimer’s disease) talked about 
hallucination, paranoia, delusions of sexual infidelity, physical aggression and screaming 
(Finkel, 2001). The BPSD include behavioural symptoms such as agitation, wandering, 
disinhibited behaviour, psychotic symptoms such as delusions and hallucinations, mood 
symptoms such as depression and anxiety and other symptoms such as diurnal rhythm 
disturbance (Sub, Greenspan & Choi, 2006). The BPSD result in negative labelling, isolation 
and decrease quality of life for the patients and in injuries, high turnover, withdrawal, 
absenteeism and burnout in nursing staff and other caregivers. They are often the decisive factor 
behind a family’s decisions to institutionalize a family member (Barton & Yaffe, 2006; 
Caballero, Hitchhock, Scharre, Beversdorf & Nahata, 2006; Masand, 2004; Pulsford & Duxbury, 
2006, Voyer et al. 2005).
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Prevalence o f Disruptive Behaviour and the BPSD
BPSD are very frequent and occur in as many as 90% of patients with dementia 
(Colombo et al., 2007). Symptoms will vary depending on the cause of dementia. In vascular 
dementia greater rates of depression are seen while in Lewy body Dementia visual hallucinations 
are more prevalent. In fronto-temporal lobe dementia symptoms of apathy and/or aggression are 
more prevalent. Dementia results in increasing cognitive symptoms that occurs in a linear 
fashion whereas the BPSD fluctuate in rate and frequency over the course of the disease and 
different symptoms appear and disappear as the disease progresses. Some side effects from the 
medications that are used to manage the BPSD also resemble symptoms ofBPSD. Preexisting 
cognitive problems also make it difficult to ascertain which symptom is caused by the disease 
and which is caused by the drugs (Davidson, 2001; Finkel, 2001).
Specific Behavioural and Psychological Symptoms
Specific behavioural and psychological symptoms include delusions and during the 
course of the illness 73% of patients with Alzheimer’s disease will experience them. The most 
common delusion is that of “people stealing things.” It occurs when the patient misplaces things. 
It often causes much distress for the patient who believes everyone is stealing things from him. 
This can cause behavioural disruptions (Finkel, 2001).
Misidentification such as “This is not my home or I want to go home” also frequently 
occurs. This belief will prompt them to pack their belongings and as they try to “get back home” 
might contribute to wandering. Hyperindentification (where they believe that people are dressing 
up as others) also sometimes happens.
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Wandering can be very dangerous especially during the winter months. It includes 
aimless walking and again, attempts at leaving home. It is one of the most common behavioural 
symptoms and prevalence can be as high as 53% (Finkel, 2001).
Visual hallucinations One common hallucination is “Look at the children in the room”. 
Hallucinations often co-occur with visual abnormalities and agnosia.
Different studies have shown Depression to affect 10 to 50% of patients with 
Alzheimer’s disease (Finkel, 2001). Tearfulness, self-deprecating comments and anhedonia are 
some of the symptoms that manifest.
Anxieties such as worries about finances, health, the future, daily events, activities, being 
alone, crowds, darkness and bathing may also occur.
Agitation such as inappropriate verbal, vocal or motor activity is also a common 
symptom and can indicate discomfort such as pain or be a side effect, such as akathisia, of 
antipsychotic medications. Agitation has been shown to be a risk factor for falls (Finkel, 2001). 
There is a difference between agitation and akathisia however. Agitation as a symptom of the 
BPSD is periodic or intermittent and reduced when the patient becomes engaged in an activity 
while akathisia which is a side effect of antipsychotic medications is continuous and persists 
even when the patient is occupied (Lesser & Hughes, 2006).
Rage such as sudden emotional or physical outbursts also happens (Finkel, 2001).
In addition to the above symptoms Stones, Stewart and Kirkpatrick, (2003) found an 
overall prevalence rate of 14% for verbally disruptive behaviour, 3% for physically disruptive 
behaviour and 12% for both verbally and physically disruptive behaviour for the elderly with 
dementia in an Ontario long-term care facility.
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Causes and Predictors o f BPSD
Causes ofBPSD are not well understood although biochemical, neuroanatomical and 
personality traits have been associated with BPSD. Physiological dysfunction such as deficits in 
dopamine activity has been found in psychosis not only in schizophrenia but in Alzheimer’s 
disease. A comparison done between aggressive AD patients and nonaggressive AD patients also 
found that aggressive patients had a higher serotonin deficit. (Mintzer, 2001).
Other studies point to the environment or caregiver responses. (Finkel 2001; Pulsford & 
Duxbury, 2006.) Earlier research stressed the importance of cognitive triggers for disruptive 
behaviour, recently however there has been an emphasis on the importance of noncognitive 
factors (Horowitz, 1997).
Causes o f Disruptive Behaviour
Stones et al. (2003) examined disruptive behaviour (verbally and physically disruptive 
behaviour) in long-term care facilities using the Minimum Data Set (2.0) and found, based on 
findings from a previous study, that the strongest predictors of disruptive behaviour related to 
delirium, untreated depression, and bladder incontinence. These findings are important because 
they relate to issues that can be treated or reversed.
Other factors that have been linked to disturbing behaviours include external factors such 
as noise pollution (bells, loud televisions and radios), lack of consistency, abruptness and 
tenseness which can all cause anxiety in residents. Limited resources and shortages o f staff in 
nursing homes often lead to unmet needs such as the failure to respond in a timely manner when 
a resident is feeling tired, depressed, dehydrated, constipated or in pain. This can lead to 
disruptive behaviour (Olson, 2002). Feelings of loss of control, self-determination and autonomy 
have also been linked to agitation and aggression in the elderly (Hall & Bocksnick, 1995).
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Impact on Caregivers
BPSD and other disturbing behaviours are very prevalent and cause much distress to 
patients, families and caregivers. The psychological and physical impact of aggressive behaviour 
on caregivers can be debilitating. Some professional caregivers believe that the acts of violence 
that are perpetuated against them are random and nonintentional; others are not so sure (Hirst, 
2000). Although these BPSD are often dismissed as trivial and part of the job, many 
professionals don’t view it that way. Some view these acts as deliberate and intentional. The 
attacks perpetuated on the caregivers by these elderly patients may prompt some caregivers to 
retaliate and this could potentially lead to a vicious cycle of negative responding or elder abuse 
(Pulsford & Duxbury 2006). Other residents are also affected. Some of the most common 
injuries to occur between residents who are aggressive towards each other are fractures, 
dislocations, bruises, lacerations and reddened areas (Shinoda et al., 2004).
Management o f Behavioural and Psychological Symptoms
Drug therapy for the elderly should be reserved for situations where nonpharmacological 
interventions have been fully explored and implemented or when severe and dangerous 
symptoms are present. Diagnosis should also ensure that sources of delirium are eliminated. 
These include medication intoxication, withdrawal reactions or drug interactions, dehydration 
and infection. An expert panel warned that other conditions need to be ruled out before 
prescribing antipsychotics as these might lead to disruptive behaviour (Alexopoulos, Streim, 
Carpenter & Docherty, 2004). Among those other conditions we find: delirium, agitated 
depression, pain (e.g., from osteoarthritis), dysuria (e.g., from infections), abdominal discomfort 
(due to constipation) and pruritis (severe itching). For the most part, the BPSD are managed with 
psychotropic medications (Alexopoulos et al., 2004).
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Psychotropic drug use with demented elderly patients is controversial because many 
controlled studies continue to raise questions as to their effectiveness and their side effects are 
numerous and dangerous. One meta-analysis found that the quality of the trials varied. Efficacy 
was found for two drugs aripiprazole and risperidone and not for olanzapine. Response rates 
were frequently not reported. Smaller effects were seen in patients with less severe dementia, 
outpatients and patients with psychosis. One third dropped out without any difference between 
drug and placebo. Cognitive test scores were also found to worsen with drugs. Small statistical 
effect of -.016 SD units were found overall and ranged between -0.11 and -.022 (Ballard et al., 
2000; Schneider, Dagerman & Insel, 2006). Psychotropic medications used to treat the BPSD 
include antidepressants, antipsychotics and antianxiety medications. This review will focus on 
the use of antipsychotics in the management of the BPSD.
A ntipsychotic M edications to Control the BPSD
Although nonpharmacological treatments (such as bright light therapy, exercise 
programs, music exposure, aromatherapy, pet therapy or one of several behavioural treatments) 
should be tried first, antipsychotic medications (which are not recommended in elderly patients 
with dementia) continue to be prescribed as an attempt to control these disruptive behaviours 
(CPS, 2007). These drugs consist of the atypical antipsychotics or second generation 
antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole and ziprasidone) and the typical 
antipsychotics or first generation antipsychotics (haloperidol, loxapine, etc).
A Canadian large scale retrospective study which analysed data between 1997 and 2003 
found that 75.2% of new users in the community started on risperidone, 19.6% on olanzapine 
and, 5.2% on quetiapine. As for the typical antipsychotics 60.2% started on haloperidol, 17.9% 
on loxapine, 10.3% on thioridazine, chlorpromazine 5.8% and perphenazine 3.5%. They found a
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similar breakdown use in the LTC cohort (Gill et ak, 2007). Another 1-year Canadian study 
found that the most commonly prescribed antipsychotic medications in LTC facilities were 
risperidone (42.4%), loxapine (28%), olanzapine (20.4%) and quetiapine (10.6%), (Hagen et al., 
2005).
The use of antipsychotics has helped some elderly patients but not all have benefited 
from using them. Reviews of placebo controlled trials reveal a high placebo response rate as well 
as modest drug effect (Streim, 2003). Controlling the BPSD with antipsychotic drugs remains 
very controversial especially when long-term use is concerned. Their effectiveness also comes 
from short term placebo-controlled studies that use strict inclusion and exclusion criteria, and 
consequently these results may not necessarily generalize to the clinical populations (Masand, 
2004). The Compendium of Pharmaceuticals Specialties 2007 (CPS), states that antipsychotics 
are contraindicated for the management of disruptive behaviour in dementia except for risperdal. 
Indications and clinical use affirm that “Risperdal may be useful in severe dementia, but only for 
the short-term symptomatic management of inappropriate behaviour due to aggression and/or 
psychosis” (p.2093). Although serious contraindications have been issued by drug manufacturers 
as a result of controlled studies, such as increased risk of death, they are still being prescribed at 
an alarming rate. The CPS (2007) Serious Warnings and Precautions states:
Increased mortality in elderly patients with dementia: Elderly patients with dementia 
treated with atypical antipsychotic drugs are at an increased risk of death compared to 
placebo. Analyses of thirteen placebo controlled trials with various atypical 
antipsychotics (modal duration of 10 weeks) in these patients showed a mean 1.6 fold 
increase in death rate in the drug-related patients. Although the causes of death were 
varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden
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death) or infectious (e.g., pneumonia) in nature (See warnings and precautions, special
populations. Use in geriatric patients with Dementia). (p.2093).
Because side effects are often worse in the elderly they pose risks that may outweigh the 
benefits.
In Canada, there is no law regarding the prescription of antipsychotic medications in 
LTC facilities. In the United States, however, a federal law was passed in 1987 (OBRA ’87) in 
response to the accumulating evidence regarding the inappropriate use of antipsychotic 
medications for the treatment of disruptive behaviour in elderly dementia patients. This law was 
intended to protect residents of nursing homes and assisted-living facilities who received 
government funding against the inappropriate use of these medications. According to this law, 
antipsychotics can only be prescribed for agitation, aggression and psychotic behaviour that is 
distressing to the patients or dangerous to others including the staff (Harvard Mental Health 
Letter, 2007). This law was enacted to prevent elderly patients with dementia from being 
drugged into a stupor.
Therapeutic Profile
The therapeutic profile of antipsychotic medications is only beginning to be studied 
extensively in the elderly. To date, the available data do not allow any definitive conclusions as 
to which symptoms are most responsive to antipsychotic drugs or how the effects vary according 
to the severity of the symptoms (Frazer, Herr, Katz & Portney, 2001). In the Risperdal 
information section of the CPS (2007) it is recommended that it be used for aggression and 
psychosis only as other behavioural disturbances remain unaffected.
A Canadian Study of 2,332 residents undertaken in 28 LTC home in Quebec in 1996 
concluded that antipsychotic medications were being prescribed for all types of disruptive
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behavioural profiles regardless of the lack of evidence as to their effectiveness. Increases in 
incidences of disruptive behaviour increased the risk of being administrated an antipsychotic 
(Voyer et al., 2005). A 1-year longitudinal study found seven behaviours associated with 
antipsychotic use in the elderly: wandering, pacing, exhibiting objectionable behaviour, making 
intolerable noises, interfering with staff, refusing staff instructions and hitting, biting and 
scratching (Burton, Rovner, German, Brant & Clark, 1995).
A Danish study reported that staff assessment independently determined the use of 
psychotropic medications including antipsychotics regardless of the presence of a psychiatric 
diagnosis. Of those elderly receiving an antipsychotic, 24% had a (Geriatric Mental Scale) GMS- 
AGECAT diagnosis. Behaviours associated with the use of antipsychotics included “becoming 
upset, fidgeting, being restless, screaming and yelling loudly” (Sorensen, Foldspang, Gulmann & 
Munk-Jorgensen, 2001, p. 148).
In one study, residents over the age of 75 and men were more likely to be treated with an 
antipsychotic than women. Restraint use, poorer mental health status, and having complicated 
dementia were also associated with its use (Burton et al., 1995). In another study, age was found 
to affect the type of antipsychotic (typical or atypical) one received. Those younger than 65 years 
of age were more likely to be prescribed an atypical antipsychotic or to be switched to one 
compared to claimants older than 65 (Dewa, Remington, Henman, Feamley & Goering, 2002).
A cross-sectional survey research of 2017 dementia patients who were either taking 
antipsychotic drugs or not taking them (recruited from residential care facilities, nursing homes, 
group dwelling for people with dementia rehabilitation units (short-term), geriatric and 
psychogeriatric units) were compared. Six of the 11 factors found to be associated with the 
prescriptions of antipsychotic were being male, younger, with lower ADL and orientation scores.
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more mobile, imposed a greater mental workload on staff and living in a group dwelling for 
people with dementia. The authors concluded that level of threat perceived by staff was related to 
whether or not one would be prescribed an antipsychotic (Lovheim, Sandmass, Kalin, Larlsson 
& Gustafson, 2006).
Another study looked the oldest old among LTC residents and found that socially 
inappropriate and disruptive behaviour were associated with the reception of an antipsychotic 
drug. Other factors such as being on a concomitant anxiolytic medication, voicing recurring 
anxious complaints, having recurring physical movements and having unsettled relationships 
were also related. Those with a sense of initiative and involvement were significantly less likely 
to be prescribed an antipsychotic. In this study, negative attitude towards others seemed to be 
related to antipsychotic medications use also (Alanen, Firme-Soveri, Noro, Leinonen, 2006a). 
A ppropriate Use o f  Antipsychotics in the E lderly
Recommendations approved by the American Health Care Financing Administration 
(HCFA) office list some conditions that are appropriate for the use of antipsychotics for the 
elderly. These include organic mental syndromes associated with psychotic or agitated symptoms 
that must include some specific behaviour such as biting, kicking or scratching that are 
substantively documented and that present a danger for the patients themselves, to others or that 
interfere with the staffs’ ability to provide care. Continuous crying out, screaming, yelling, or 
pacing and psychotic symptoms such as hallucinations, delusions and paranoia that impairs 
functional capacity have also been deemed appropriate for their use.
Behaviours that occur in isolation such as wandering, restlessness, anxiety, insomnia, and 
indifference to surroundings, nervousness, unspecified agitation, poor self-care, impaired
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memory, depression, unsociability, fidgeting and uncooperativeness does not warrant the use of 
antipsychotics (Motsinger, Perron, & Lacy, 2003).
A Canadian 1-year comparative descriptive design study of two LTC centres was 
conducted on 332 residents. Data on antipsychotic drug use were extracted from patient charts 
and pharmacy records. Overall, 25% of the residents were prescribed an antipsychotic as p.r.n (as 
needed). Most did not receive any but some received as many as 90 doses per month. Less than a 
third of the prescriptions had a reason given for their use. The most common reason given (64%) 
was continuation of previous prescription. The other reasons included “agitated or aggressive 
behaviour” (29.7%), “delusional” (4.4%), and “yelling or calling out” (2.2 %). In this study, 
residents had been receiving antipsychotic medication for an average of 45 weeks and 16% 
showed evidence of an attempt at dose reduction within the first 6 months (Hagen et al., 2005). 
Prevalence o f Antipsychotic Medication to Treat the BPSD
In a Danish study of nursing home residents 56% were prescribed a psychotropic 
medication of which 21% received an antipsychotic drug, typical and atypical (Sorenson, 
Foldspand, Gulmann & Munk-Jorgensen, 2001). A 3-year retrospective and cross-sectional study 
was conducted on the RAI-MDS (2.0) data originating from 16 hospital-based LTC institutions 
(55 wards) and 25 residential homes in Finland. Forty-two percent of the elderly residents 
received one or more antipsychotic medication in 2001. Mean use was reduced to 39% in 2002 
and 2003. Of those with dementia 45% received an antipsychotic in 2001,43% in 2002 and 41% 
in 2003. Of those with behavioural problems 59% received an antipsychotic in 2001, 57% in 
2002 and 55% in 2003 (Alanen, Finne-Soveri, Noro & Leinonen, 2006b). A Canadian 1-year 
comparative descriptive design study found prevalence rates that ranged from 22% to 37% 
depending on the facility (Hagen et al., 2005).
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Prevalence rates have increased since the introduction of the newer antipsychotic drugs. 
A Canadian study was conducted to examine overall trends in antipsychotic use in the elderly 
and the disadvantaged populations of Ontario between 1992 and 1998. During that time period, 
claimants of the Ontario Drug Benefit program grew by 1% whereas the number of claimants 
prescribed an antipsychotic drug grew by 25%. At the same time growth in expenditure 
increased by nearly 250%. At the time of the passing of the Omnibus Budget Reconciliation Act 
of 1987 (OBRA) prevalence rates of antipsychotic medications in US nursing homes were as 
high as 40%. (Hagen et al., 2005).
Typical or Conventional Antipsychotics
The typical or first generation antipsychotics have been widely prescribed since the 
1950s. These medications block the dopamine (D2) receptor in the mesolimbic system which in 
turn reduces the positive symptoms of psychosis such as delusions and hallucinations. Drugs 
such as haloperidol, thioridazine, fluphenazine, loxapine and perphenazine have shown modest 
efficacy in the management of the BPSD (Ryan, 2003). They have also been linked to more rapid 
cognitive decline in patients with dementia (Schneider et al., 2005). The D2 blockade in the 
nigrostriatal pathway also causes extrapyramidal symptoms such as akathisia, acute dystonia, 
tardive dyskinesia and the drug-induced Parkinsonism. The extrapyramidal symptoms such as 
tardive dyskinesia are associated with incoordination, feeding problems, disfigurement, social 
isolation, falls and fractures (Ryan, 2003). The D2 blockade in the tuberoinfundibular pathway 
increases serum levels of prolactin. This can cause breast tenderness, galactorrhea or erectile 
dysfunction (Motsinger et al., 2003).
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Haloperidol (haldol)
Hoeh et al. (2003) reported that significant improvement was seen in disruptive 
behaviour in patients with dementia with haloperidol (haldol) at 2-3 mg per day but not at low 
doses of 0.5 to 0.75 mg per day. Post-hoc analysis of an 18 week randomized double-blind 
crossover head-to-head trial of haloperidol vs risperidone in 114 nursing home residents found 
haldol to be significantly inferior to risperidone in terms of efficacy in treating physical sexual 
advances, pacing and aimless wandering, intentional falling, hoarding things, performing 
repetitive mannerism and repetitive sentences or questions, complaining and negativism. More 
side effects were also reported for haldol (Suh & Shahet, 2006).
Side effects o f haloperidol. Moderate to severe extrapyramidal side effects (EPS) or 
neuroleptic-induced movement disorders are problematic and common with Haldol. In one study 
as much as 20% of the patients reported them (Streim, 2003). EPS can be classified into acute or 
tardive syndrome. Among the former we find Parkinsonism, dystonia and akathisia.
Parkinsonism side effects resemble the disease itself. These side effects tend to appear a 
couple of weeks after initiation of treatment. Bradykinesia is an extreme slowness and stiffiiess 
of movement in which rigidity predominates. An impaired righting reflex accompanied by 
excessive salivation and autonomic instability can sometimes be observed.
Akathisia is a side effect that is commonly mistaken for agitation or worsening of the 
psychosis. It is defined as a movement disorder characterized by a feeling of inner restlessness 
and a compelling need of being in constant motion and by actions such as rocking while standing 
or sitting, lifting the feet as if marching on the spot and crossing and uncrossing the legs while 
sitting. It is often accompanied by feelings of irritability and aggression (Leikin & Lipsky, 2000).
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Akathisia also decreases with age appearing in 15% of patients over the age of 65 compared to 
90% in younger patients (Fabbrini, Barbanti & Aurilia, 2001). Tardive Dyskinesia (TD) 
develops from chronic exposure to the typical antipsychotics and is much worse in elderly 
patients. It can be irreversible. Although considered a mild disorder it can become debilitating in 
some patients (Fabbrini et al., 2001). The most common form of TD is the bucco-lingual- 
masticatory syndrome of mouth, jaw, and tongue movements, chewing and lip sucking. Besides 
aesthetic problems which may add to the social isolation of older people, some have difficulties 
keeping dentures in their mouth or eating. Sometimes pharyngeal involvement may cause 
aspiration pneumonia. Diaphragmatic involvement may also worsen due to respiratory 
dysfunction. Speech may also be severely impaired (Fabbrini et al., 2001). About 60% of elderly 
patients suffer from this most common form of TD. Those who are treated with haloperidol for 
the first time will develop tardive dyskinesia at a rate of 25% to 50% per year. Risk factors for 
tardive dyskinesia are old age, female gender, nonschizophrenic and presence of acute EPS. 
Intermittent dosing is also associated with higher rates of tardive dyskenisia (Wirshing, 2001). 
These numerous side effects have caused a shift toward the atypical antipsychotics (Ryan, 2003). 
A typical Antipsychotics
The atypical antipsychotics have significantly replaced the typical antipsychotics because 
they cause fewer side effects especially those that relate to the movement disorders (Smith & 
Beier, 2004). They include risperidone, olanzapine, quetiapine and clozapine. Newer 
antipsychotic drugs have both serotonergic and dopaminergiv activity (Lawlor, 2004). Their 
action on both systems makes them effective in treating the positive and negative symptoms of 
psychosis. Alterations in the serotonin system are related to aggression and the atypical 
antipsychotics affect the serotonin (5-HT) system. Evidence also indicates a clear deficit in
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serotonin receptors in Alzheimer’s disease (Mintzer, Streim & Ryan, 2003). Practice guidelines 
from the American Psychiatric Association inform us, however, that these medications have been 
associated with glucose dysregulation, hyperlipidemia, and weight gain. Increased risk of 
cerebrovascular events including stroke was also found in clinical trials of risperidone and 
olanzapine in geriatric patients with dementia-related psychosis (Rabins, 2006). Risperidone and 
olanzapine are commonly prescribed in dementia patients (Katz et al., 2007).
In 1998, Expert Consensus Guidelines recommended the use of the atypical 
antipsychotics risperidone and olanzapine or a high-potency conventional antipsychotic such as 
haloperidol as first-line therapy for the treatment of the BPSD (De Deyn et al., 2004). In 2002, 
new data prompted Health Canada to advise physicians “to reassess the risks and benefits in their 
patients with dementia and to counsel caregivers to immediately report signs and symptoms of 
cerebrovascular adverse events” (De Deyn et al., p. 117).
Following the Canadian advisory, the U.S. Food and Drug Administration (FDA) 
mandated that additional warnings regarding the increased risk of cerebrovascular events be 
added to all prescribing information (Schneider et al., 2005). In March 2004, the UK committee 
of safety of Medicines (CSM) went a little further in their recommendations and informed 
clinicians that risperidone and olanzapine should not be used to treat the BPSD because of the 
increased risk of stroke with both drugs and the increased risk of mortality with olanzapine. The 
CSM additionally provided these guidelines: Use of risperidone in the treatment of acute 
psychosis should be limited to short term use under specialist advice. Preexisting risks of 
cerebrovascular event or disease such as previous history of stroke or transient ischaemic attack 
(TIA), hypertension, diabetes, atrial fibrillation and current smoking should be evaluated prior to 
initiating drug treatment in all patients. The CSM also provided a list of Web sites with
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information on nonpharmacological interventions. The advice was supplemented by guidance 
issued by the Royal College of Psychiatrists, Royal College of General Practitioners, British 
Geriatric Society and Alzheimer’s disease Society (Shah, 2006).
Scales Used to Assess BPSD
In order to conduct clinically objective assessments of the BPSD in controlled drug trials 
three different scales are usually used. These are the Behavioural Pathology in Alzheimer’s 
disease Rating Scale (BEHAVE-AD), the Cohen-Mansfield Agitation Inventory (CMAI), and 
the Neuropsychiatrie Inventory (NPI). These scales have been shown to be sensitive, valid, and 
reliable measures.
The BEHA VE-AD is a simple scale that includes 2 parts -symptomatology and global 
rating. Symptomatology assesses 25 symptoms in seven categories; delusions, hallucinations, 
aggressiveness, activity disturbances, affective disturbances and anxiety. In the delusional 
cluster, for example different symptoms are examined such as: people are stealing things, one’s 
house is not one’s home, spouse (or other caregiver) is an imposter, delusion of abandonment, 
delusion of infidelity, suspiciousness/paranoia. Caregivers are asked to rate the patient’s 
behaviour on a 4-point scale over the preceding 2 weeks. For example for “one’s house is not 
one’s home” the scoring would be 0 -  not present', 1 = conviction that the place in which one is 
residing is not one’s home', 2 = attempt to leave domicile to go home', 3 — violence in response to 
attempts to forcibly restrict exit. The total maximum score is 75. The global assessment part of 
the scale is also completed by the caregiver and it assesses the severity of the BPSD: 0 = not at 
all troubling', 1 = mildly troubling to the caregiver or dangerous to the patient', 2 = moderately 
troubling to the caregiver or dangerous to the patient', 3 = severely troubling or intolerable to 
the caregiver or dangerous to the patient.
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The CMAI is another scale that is frequently used to assess the BPSD. This 7-point rating 
scale assesses the frequency of 29 agitated behaviours. These are pacing, aimless wandering, 
inappropriate dress or disrobing, spitting (including at meals), cursing or verbal aggression, 
constant unwarranted requests for attention or help, repetitive sentences or questions, hitting 
(including self), kicking, grabbing onto people, pushing, throwing things, strange noises (weird 
laughter or crying), screaming, biting, scratching, trying to get into a different place (e.g., out of 
the room, building), intentional falling, complaining, negativism, eating/drinking inappropriate 
substances, hurt self or other (cigarette, hot water, etc,), handling things inappropriately, hiding 
things, hoarding things, tearing things or destroying property, performing repeated mannerisms, 
making verbal sexual advances, making physical sexual advances and general restlessness. 
Caregivers must be properly trained to complete the scale. Each item is scored with reference to 
the past 2 weeks and is rated as 1 = never, 2 - 1  time per week, I» -  1-2 times per week, 4 = 
several times per week, 5 = once or twice per day, 6 = several times per day, 7 = several times 
per hour. The total maximum score is 203.
The NPI assesses 12 behavioural symptoms of dementia. The behaviour include 
delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, 
disinhibition, aberrant motor behaviour, night-time behaviour disturbances as well as appetite 
abnormalities. Caregivers rate severity on a scale of 1,2 or 3 (mild, moderate, severe) and 
frequency 1 to 4 . 1 =  occasionally, less than once per week and 4 = very frequently, once or 
more per day or continuously. The total maximum score for each domain is 12. Caregivers also 
assess their own level of distress (De Deyn & Wirshing, 2001).
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Antipsychotics and the Increased Risk o f  Death
A retrospective study of 22,890 patients 65 years of age or older who began receiving an 
antipsychotic between 1994 and 2003 was done to compare risk of death after initiation of an 
antipsychotic medication whether typical or atypical. It was found that both typical and atypical 
antipsychotics were associated with risk of death and that the conventional or typical ones had an 
even greater risk (Wang, Schneeweiss, Avom & Fisher, 2005).
A Canadian retrospective cohort study was conducted on a total of 27,259 older adults 
who were followed between April 1997 and March 2003. Information was taken from several 
databases including pharmacy records from the Ontario drug benefit program, hospitalization 
records from the Canadian Institute for Health Information Discharge Abstract Database, 
physician billing information for inpatient and outpatient services from the Ontario Health 
Insurance Plan, basic demographic information and vital statistics from the Registered Persons 
Database. Comparisons between new users of atypical antipsychotics vs. no-antipsychotic use 
and conventional versus vs. atypical antipsychotics were done. Two cohorts were examined; 
community dwellers and long-term care residents. Statistically significant increase in death was 
found between atypical users and nonusers 30 days after having started antipsychotics with both 
cohorts. Typical antipsychotic use was also associated with a higher risk for death at all time 
points (after 30 days, 60 days, 120 days and 180 days; Gill et al., 2007).
A meta-analysis of 15 randomized placebo-controlled drug trials also found that death 
occurred more often among patients who received an atypical antipsychotic versus those who did 
not (Schneider et al., 2005). In April 2005, a public health advisory was issued by the FDA 
regarding the increased risk of death for dementia patients treated with antipsychotics. Health 
Canada issued a similar warning in Jime 2005 (Gill et al., 2007). Antipsychotic drugs however
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continue to be prescribed for the management of the BPSD (Layton, Harris, Wilton, Saad & 
Shakir, 2005).
Risperdal or Risperidone
Risperidone has been extensively researched and is now the most widely prescribed 
antipsychotic in the elderly (Tune, 2001). It has been around since 1993. The Compendium of 
Pharmaceuticals Systems (CPS) indicates that Risperdal may be useful in severe dementia for the 
short-term symptomatic management of inappropriate behaviour due to aggression and psychosis 
but warns that other behavioural disturbances remain unaffected by risperdal treatment. Evidence 
coming from short term placebo controlled studies supports the efficacy of risperidone in treating 
symptoms of aggression, agitation and psychosis. Dosage should be started at 0.25 mg a day and 
incrementally increased until the desired effect is reached because extrapyramidal symptoms 
increase as the dose is increased. Mean dosage found in a couple of studies was at 1.2 to 1.2 mg 
per day (Motsinger et al., 2003).
A 12-week randomized placebo controlled trial of Risperidone conducted for the 
treatment of aggression, agitation and psychoses in nursing home patients with dementia found 
greater improvement on all CMAI subscales which measured total aggression such as physical 
(hitting, wandering.) verbal (screaming, grunting) and agitated behaviour compared to the 
placebo group at weeks 4 through 12. Positive effects of risperidone was also found for both 
aggressive and nonaggressive, agitated behaviour. A significant improvement on the BEHAVE- 
AD (Behavioural Pathology in Alzheimer’s disease) was also found in the risperidone group.
The more psychotic symptoms were present at baseline the more effective risperidone was 
relative to placebo. The clinical impression of change assessed by both caregivers and
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investigators also found significant improvements in the drug group over placebo. Reduced 
aggression was found whether patients had a psychosis or not (Brodaty et al., 2003).
Another 12-weeks randomized control trial of risperidone found a reduction in total score 
of the BEHAVE-AD. A 50% response reduction on the BEHAVE-AD total score was found in 
45% of those receiving Img/day, 50% of those receiving 2 mg a day and 33% of those receiving 
a placebo. Significant improvement was seen on the aggression items only. All other subscales 
differences were not significant. A comparison of violence rates at baseline found a 65% 
reduction in those who received the drug (regardless of dosage) versus 42% reduction in those 
who received the placebo. The Cohen-Mansfield Agitation inventory (CMAI) showed 
significantly greater improvements for those receiving 2 mg and 1 mg per day.
A meta-analysis of 4 large placebo-controlled clinical trials of risperidone in dementia 
found that it significantly improved scores on the BEHAVE-AD and CGI scale compared to 
placebo. It was also found that patients who had more severe symptoms responded better to the 
risperidone treatment than those who had less severe symptoms when compared to the placebo 
treated group (Katz et al., 2007).
Side effect o f risperidone.
Common side effects associated with risperidone include extrapyramidal symptoms, 
dizziness, hypotension, nausea, weight gain, sleep disturbance, and sexual dysfunction (Katz et 
al., 2007; Razaq & Samma, 2004). Postural hypotension may predispose to falls and fractures 
(Ryan, 2003). In one study, rates of extrapyramidal symptoms ranged from 12 (70.4%) in the 
placebo group to 35 (21.2%) in the 2 mg/day drug group. Somnolence and peripheral edema was 
also found to increase as the dose was increased. In the placebo group, 13 (8.0%) reported 
somnolence and 9 (5.5%) reported peripheral edema. In the 2 mg/day group 46 (27.9%) reported
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somnolence and 30 (18.2%) reported peripheral edema. They also found that cerebrovascular 
adverse events and all-eause mortality were observed more frequently in the risperidone treated 
group compared to placebo although it was not statistically significant (Katz et al., 1999).
In April 2003, Janssen Pharmaceutica Products, L.P., Titusville, New Jersey, the 
manufacturer of risperidone informed health care providers about a new warning coneeming 
cerebrovascular adverse events (CAE). The warning stated that there was a significantly higher 
incidence of CAE in patients treated with risperidone compared to those treated with placebo.
The warning further stated that Risperdal was not approved for the treatment of patients with 
dementia-related psychosis. The warning received by Canadian physicians in October 2002 cited 
the rate of CAE of 4% of the risperidone group versus 2% in the placebo group (Smith & Beier, 
2004).
Following the warnings concerning the safety of risperidone and olanzapine in 2004 by 
the U.K. Committee of Safety of Medicine, a retrospective analysis of three PEM studies (PEM 
studies are conducted by the Drug Safety Research Unit following a newly marketed drug 
prescribed in primary care settings in England) was conducted. They examined and compared the 
incidence rates of cerebrovascular adverse events that were reported within the first 6 months of 
treatment initiation. Confounding variables such as age, sex, and indication (dementia or other) 
were also examined. They found that cases of CVA/TIA occurred predominantly in older 
individuals and that it tended to increase with age but it was unclear if this relationship was 
linear. They also found that 50% of cases had occurred within the second month of treatment 
with risperidone. For quetiapine 50% had occurred by the third and fourth month. All three drug 
cohorts (risperidone, quetiapine and olanzapine) had a significant association with CVA/TIA.
The three variables age, sex, and indication were also significantly related. Females prescribed
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risperidone had a significantly higher incidence rate of CVA/TIA event compared to males. It 
was also foimd that patients prescribed risperidone for dementia were significantly more likely to 
experience these events compared to those treated with risperidone for other reasons (Layton et 
al., 2005). The CPS, 2007 also indicates that six 4 to 6 weeks placebo-controlled trials found a 
3% incidence rate of CVA in the Risperidone treated group versus 1% in the placebo group. Five 
patients died in the risperidone group versus 1 patient in the placebo group. A double blind 
comparison of risperidone and olanzapine for the acute treatment of dementia related behavioural 
disturbances found 113 adverse events. Adverse events were similar in both groups and the most 
common were drowsiness, falls and EPS (Fontaine et al., 2003).
Although the CPS, 2007 states that risperdal may be usefiil in treating aggression and 
psychosis it also warns about the increased mortality risk in elderly patients with dementia. 
General considerations warn that a disruption of the body’s ability to reduce core body 
temperature has been attributed to antipsychotic drugs. Vigilance is important when treating 
patients who may be experiencing dehydration or receiving a concomitant medication with 
anticholinergic activity.
Carcinogenesis studies of risperidone done on rats show statistically significant increases 
in pituitary gland adenomas, endocrine pancreas adenomas and mammary gland 
adenocarcinomas, other side effects listed in the CPS 2007 include orthostatic hypotension, 
tachycardia, rare cases of syncope, cardiac arrhythmias and first degree AV-block or ECG 
changes. Because patients with a history of cardiac disorders have been excluded from clinical 
trials, risperdal should be used with caution in patients with cardiovascular diseases.
According to the CPS 2007, epidemiological studies also suggest an increased risk of 
treatment-emergent hyperglycemia-related adverse effects. Thus patients treated with
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antipsychotics should be monitored for hyperglycemia such as polydipsia (excessive drinking), 
polyuria (excessive urinating), polyphagia (excessive eating), and weakness. Dysphagia has also 
been associated with antipsychotics medications. In controlled clinical trials, patients treated 
with risperidone also had higher prolactin levels than patients treated with haldol. Risperidone 
may also have an antiemetic effect. This effect could mask signs of toxicity due to overdosage 
with other drugs, or mask other diseases (CPS, 2007).
Rare cases of priapism (prolonged and painful erections) have also been reported. 
Neuroleptic Malignant syndrome is a fatal symptom complex that has been reported in patients 
taking antipsychotic drugs, including risperdal. Clinical manifestations include hyperthermia, 
muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic 
instability such as irregular blood pressure, tachycardia, cardiac arrhythmias, and diaphoresis. 
Incidences of somnolence are higher in patients treated with risperidone compared to placebo or 
haldol. Risperdal as with all antipsychotics lowers the seizure threshold and in some patients 
seizures have occurred (CPS, 2007).
Patients with Parkinson’s disease or Dementia with Lewy Bodies should not take 
risperdal as it increases the risk of Neuroleptic Malignant Syndrome. Symptoms include 
confusion, obtundation (diminished alertness or consciousness), postural instability with frequent 
falls and extrapyramidal symptoms. In the recommendations for special populations section, it is 
recommended that treatment of risperdal be started at low doses because geriatric patients have 
decreased renal, hepatic and cardiac function and they have an increased risk of postural 
hypotension. Again the same warning regarding the increased risk of mortality in elderly patients 
with dementia treated with antipsychotics can be read. Two of four placebo-controlled trials in
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elderly patients with dementia found a higher incidence of mortality in patients treated 
concomitantly with furosemide and risperidone (CPS, 2007).
Olanzapine (Zyprexa)
Evidence indicates that olanzapine is an effective agent against psychotic and behaviour 
symptoms in patients with Alzheimer’s disease (Motsinger et al., 2003). A 6-week placebo 
controlled trial found that olanzapine was effective in reducing the emergence of psychosis in 
Alzheimer’s disease in patients who had no such psychotic symptoms at baseline compared to 
the placebo group (Clark, Street, Feldman & Breier, 2001).
A large-scale, double-blind placebo controlled trial in which 652 patients from 61 
different sites participated, tested the difference between 5 treatment groups. Doses of Img, 2.5 
mg, 5mg, 7.5mg and placebo were analyzed. Greater improvements were seen on the psychosis 
total score for the 7.5 mg group and the magnitude of improvement became greater as the dose 
increased. The item of the NPI/NH that appeared to be most affected by olanzapine was 
agitation/aggression. Other items that showed greater improvements were anxiety, 
apathy/indifference, delusions, euphoria and irritability/lability (De Deyn et al., 2004).
According to the CPS however, olanzapine or zyprexa is not indicated in elderly patients with 
dementia.
Side effects o f olanzapine.
Clark et al. (2001) found a significant difference between the olanzapine treated groups 
who received a dose of 5-mg and 15-mg a day as compared to the placebo group in “Abnormal 
gait”, a term from Coding Symbols for Thesaurus of Adverse Reaction Terms comprising 
“leaning”, “limp”, “stooped posture” and “unsteady gait”. Another adverse reaction that was 
significantly different between the treatment and placebo group was somnolence. Somnolence
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and sedation causes impairment in carrying out activities of daily living (Ryan, 2003). In De 
Deyn et al.’s large scale study, pairwise comparisons showed a significantly greater mean 
increase in body weight for both the 5 mg and 7.5mg compared to the placebo group. Prolactin 
levels were also different overall with the 7.5 mg group showing a significantly greater increase 
than the placebo.
In Fontaine et al. (2003), side effects reported were frequent, mild and similar (drowsiness, 
falls and EPS) to those reported for risperidone but one patient in the olanzapine group had 2 
serious adverse events: an episode of asystole (at which time olanzapine was discontinued) 
followed 6 days later by a brain stem stroke.
Increased risks o f diabetes.
In a retrospective study, Koro et al. (2002) assessed the effects of olanzapine and 
risperidone on the risk of diabetes in patients with schizophrenia. Compared to those not taking 
antipsychotics those who took olanzapine had a significant increased risk of developing diabetes. 
No such increase was found in those taking risperidone.
In a retrospective study of 590 patients it was found that patients treated with olanzapine 
as well as those treated with clozapine and haloperidol were found to have elevated glucose and 
lipid levels compared to baseline. Those who received olanzapine and clozapine had statistically 
significant increases in triglyrides levels compared with the other groups. Elevated glucose and 
triglyceride levels increase the risk for coronary artery disease (Wirshing, Boyd, Meng, Ballon, 
Marder & Wirshing, 2002).
As with all antipsychotics, the CPS (2007) includes a serious warning of increased 
mortality rate in elderly patients. Similar side effects that were reported in the CPS for 
risperidone apply to olanzapine. These are Neuroleptic Malignant Syndrome, weight gain, body
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temperature regulation, hypotension and syncope, hyperglycaemia, hyperprolactinemia, 
antiemetic effect, rare cases of priapism, rare cases of leucopenia (a decrease in white blood 
cells), transient transaminase elevations (indicators of hepatic injury), tardive dyskinesia, 
seizures, mild elevation of uric acid (may cause hypertension), overall mortality, dyphagia and 
cardiovascular events in elderly patients with dementia.
In schizophrenia trials (CPS 2007) adverse events reported included headache, pain, 
abdominal pain, back pain, chest pain, neck rigidity, intentional injury, postural hypotension, 
tachycardia, hypotension, constipation, dry mouth, gamma glutamyl transpeptidase increase, 
increased appetite, ALT increase, edema, peripheral edema, AST increase, creatine 
phosphokinase increase, arthralgia (joint pain), twitching, somnolence, agitation, insomnia, 
nervousness, hostility, dizziness, anxiety, personality disorder, akathisia, hypertonia, speech 
disorder, tremor, amnesia, drug dependence, euphoria, neurosis, rhinitis (runny and congested 
nose), cough increase, pharyngitis, fungal dermatitis, rash, amblyopia, blepharitis, eye disorder 
comeal lesion, menstmal disorder and tremor and asthenia.
Quetiapine
Quetiapine or seroquel has shown promises in treating psychosis in elderly patients with 
Alzheimer’s disease and Parkinson’s disease without exacerbating movement disorders in those 
suffering from Parkinsons’. It was introduced to the U.S. market in 1997 (Madhusoodanan, 
Brenner, Gupta & Bogunovic, 2001). This dmg was not only found to be clinically effective but 
also improved the EPS noted at baseline (Mintzer et al., 2003). Initial dosage should start at 12.5 
mg and titrated every 3 to 5 days until the desired effect is reached or side effects start to emerge 
(Motsinger et al., 2003). Tariot (2004) suggest an initial dosage of 25 mg per day with
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incremental increases in dose to target 100 to 150 mg per day. The CPS 2007 however indicates 
that Seroquel is not indicated in elderly patients with dementia.
Quetiapine’s antipsychotic activity is mediated through activity at dopamine (DA2) 
receptors and serotonin (5-HT2). Pharmacodynamic antagonism is also seen at histaminergic and 
adrenergic receptors. An open label, multicenter, uncontrolled trial was conducted to assess the 
long-term tolerability, safety, and clinical benefit of quetiapine in elderly patients with psychotic 
disorders over the course of 1 year. Overall 89 (48%) patients completed the 52 weeks study. A 
significant difference between those who completed the study and those who did not was a 
gradual increase in mean daily dose. These findings suggest using a slow and steady dose 
increase in elderly patients (Tariot, 2004).
Side effects o f Quetiapine.
Common side effects include sedation, headache and orthostatic hypotension. Although a 
causal relationship between Seroquel and lens changes have not been established, lens changes 
have been observed in patients during long-term use of Seroquel (CPS 2007). Screening for 
cataract formation and a general eye exam should also be done at initiation of treatment and at 6 
months intervals (Motsinger et al., 2003). In Tariot’s (2004) 1-year uncontrolled exploratory 
study side effects that occurred in more than 10% of the patients were somnolence (31%), 
accidental injury (24%), dizziness (17%), agitation (16%), postural hypotension (15%), 
constipation (13%), urinary tract infection (11%), insomnia (10%) and abnormal 
electrocardiogram (10%). Two patients withdrew from the study due to somnolence, 2 due to 
dizziness, 1 due to postural hypotension and another because of tachycardia (rapid heart rate). 
Weight gain was also reported by 4 patients and weight loss by 11 patients. According to the 
CPS, 2007 all of the side effects previously mentioned with risperidone and olanzapine apply to
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quetiapine. A serious warning of increased mortality rate in elderly patients with dementia is 
again mentioned in the CPS, 2007.
Clozapine (Clozaril)
A randomized, double-blind placebo controlled trial was conducted to assess the efficacy 
of low dose clozapine to treat psychosis in patients’ with Parkinson’s disease in 60 patients at six 
different sites over a 14 month period. Significant improvements were found on the Clinical 
Global Impression Scale, the Brief Psychiatric Rating Scale and on the Scale for the Assessment 
of Positive Symptoms. It was also found to improve tremor and it did not worsen Parkinsonism 
symptoms (Friedman, Lannon, Cornelia & Factor, 1999). The American Academy of Neurology 
stated that clozapine was the most effective treatment of drug induced psychosis in patients with 
Parkinson’s disease (Motsinger et al., 2003). Clozapine produces little or no prolactin elevation 
(CPS, 2007). Clozaril is indicated in the management of symptoms of treatment resistant 
schizophrenia, it was found to improve both positive and negative symptoms.
Side effects o f Clozapine.
Adverse effects are agranulocytosis (an acute disease marked by a deficit or absolute lack 
of granulocytic white blood cells), seizures, age-related delirium, cardiac effects, sedation and 
anticholinergic effects (Tariot, 2000). Agranulocytosis has a fatality rate as high as 30% thus 
Clozaril is only available through a distribution system CSAN that ensures weekly or bi-monthly 
haematological testing. This testing is required before prescribing another periods supply. 
Because of the high fatality risk this drug is usually prescribed as a last resort to schizophrenic 
patients who fail to show acceptable response to the conventional antipsychotics (Motsinger et 
al., 2003). Anticholinergic effects lead to confusion, memory impairment, blurred vision, urinary 
retention, constipation and diy mouth (Ryan, 2003).
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Clozapine causes drooling in about 30 to 35% of patients. This drooling occurs more 
frequently at night because patients are unable to swallow as much as they do during the day 
(Wirshing, 2001). On rare occasions patients have reported an intensification of dream activity. 
Rapid eye movement (REM) sleep was found to be increased to 85% of the total sleep time. In 
those patients REM sleep occurred almost immediately after falling asleep. As with typical 
antipsychotics, clozapine increases delta and theta activity and slows dominant alpha 
frequencies. Enhanced synchronization occurs, and sharp wave activity and wave complexes 
may also develop (CPS, 2007).
Haematopoietic reactions are more likely to occur with clozapine. An increased risk of 
myocarditis, pericardidis, pericardial effusion and cardiomyopathy, heart failure, myocardial 
infarction and mitral insufficiency have been reported in association with clozapine and 
sometimes fatalities have occurred. Other adverse events include: orthostatic hypotension with or 
without syncope, tachycardia, ECG repolarization, congestive heart failure, sudden unexplained 
death, Neuro Malignant syndrome, tardive dyskinesia, drowsiness/sedation (39%), 
dizziness/vertigo (19%), headache, tremor, syncope, disturbed sleep/nightmares, restlessness, 
hypokinesia, agitation, rigidity, akathisia, confusion, fatigue, insomnia, hyperkinesia, weakness, 
lethargy, ataxia, slurred speech, depression, epileptiform movements/myoclonic jerks, anxiety, 
chest pain, angina, ECG change/cardiac abnormality, constipation, nausea, abdominal 
discomfort/heartburn, nausea/vomiting, diarrhea, liver test abnormality, anorexia, urinary 
abnormalities, incontinence, abnormal ejaculation, urinary urgency/frequency, urinary retention, 
salivation, sweating, dry mouth, visual disturbances, rash, muscle weakness, pain (back, neck, 
legs), muscle spasm, muscle pain, ache, throat discomfort, dyspnea, shortness of breath, nasal
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congestion, leucopenia/decreased WBC/Neutropenia, Eosinophilia, fever, weight gain, tongue 
numbness or soreness (CPS, 2007).
The 10 most frequently reported side effects in the CPS, 2007 manual include salivary 
hypersecretion, somnolence, weight increase, anxiety, depression, dizziness (excluding vertigo), 
psychotic disorder, suicidal ideation, constipation, and insomnia. Other adverse events that were 
reported at a rate lower than 1% are loss of speech, anemia, tics, poor coordination, 
delusions/hallucinations, involuntary movement, stuttering, dysarthria, amnesia/memory loss, 
histrionic movements, libido increase or decrease, paranoia, shakiness, parkinsonism, irritability, 
edema, palpitations, phlebitis/thrombophlebitis, cyanosis, premature ventricular contraction, 
bradycardia and nose bleed, ischemic changes, arrhythmias, abdominal distention, 
gastroenteritis, rectal bleeding, nervous stomach, abnormal stools, hematemesis, gastric ulcer, 
bitter taste and eructation, dysmenorrhea, impotence, breast pain/discomfort, vaginal 
itch/infection, numbness, polydypsia, hot flashes, dry throat, mydriasis, pruritus, pallor, eczema, 
erythema, bruise, dermatitis, petechiae and urticaria, twitching, coughing, pneumonia/pneumonia 
like symptoms, rhinorrhea, hyperventilation, wheezing, bronchitis, laryngitis, sneezing, 
leukocytosis, chills/chills with fever, malaise, appetite increase, ear disorder, hypothermia, eyelid 
disorder, blood shot eyes, nystagmus. Other voluntary reports include: delirium, exacerbation of 
psychosis, myoclonus, overdose, paresthesia, possible mild cataplexy, status epilecticus, acute 
pancreatitis, dysphagia, fecal impaction, intestinal obstruction/paralytic ileus, salivary gland 
swelling, cholestasis, hepatitis, jaundice, nephritis, hypersensitivity reactions, photosensitivity, 
vasculitis, erythema multiforme, Stevens-Johnson syndrome, hyperglycemia, 
ketoacidosis,/hyperosmolar coma, hyperuricemia, hyponatremia, weight loss, impaired glucose 
tolerance, diabetes aggravated, hypercholesrolemia and hypertriglyceridemia, myasthenic
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syndrome, rhabdomyolysis, aspiration, pleural effusion, respiratory arrest, deep vein thrombosis, 
elevated haemoglobin/hematocrit, ESR increased, pulmonary embolism, sepsis, thrombocytosis, 
thrombocytopenia, thrombocythaemia, narrow angle glaucoma and CPK elevation (CPS, 2007). 
Issues in the Use o f Antipsychotics
The numerous adverse events found in the newer antipsychotic drugs may offset their 
advantages. Improvements in symptoms do not necessarily lead to improvement in overall 
quality of life for patients and their caregivers (Ballard et al., 2001). It is commonly accepted that 
all drugs have risks that must be accepted along with their benefits but at what cost (Gill et al., 
2007). Some researchers have concluded that antipsychotic use in dementia has been excessive, 
inappropriate, and poorly monitored (Lawlor, 2004).
A 3-month randomized placebo controlled antipsychotic (neuroleptic) discontinuation 
study was conducted to assess the benefits of stopping the use of antipsychotic medication in 
people scoring below the median score for behavioural symptoms at baseline. Impact on quality 
of life was also examined. Most patients with dementia (67%) who had stable behaviour and had 
been receiving an antipsychotic for more than 3 months did not experience deterioration in 
behavioural symptoms when the treatment was discontinued. Patients who scored lower than 14 
on the NPI had a better outcome with regard to agitation and showed a trend towards a reduction 
in developing behavioural problems. Those who scored higher than 14 however, were 
significantly more likely to develop marked behavioural problems if they did not continue to 
receive antipsychotic treatment. Thus discontinuing antipsychotic treatment in patients with a 
lower NPI score does not appear to exacerbate behavioural symptoms. Given the numerous side 
effects of these medications this study supports discontinuing treatment in some patients (Ballard 
et al., 2004).
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A 1-year follow-up study of the BPSD in care environments foimd high rates of 
spontaneous resolution. Agitation resolved independently of medication in 45% of the cases, 
delusions resolved independently in 60% of the cases and depression in 60% of the cases. Thus 
prescribing antipsychotic medications for long period of time might not be necessary. Short 
periods of intervention targeted at specific symptoms may be more effective and much less 
harmful to the patient (Ballard et al., 2001).
Another 1-year prospective study found no difference in the duration of symptoms 
between those taking and not taking antipsychotics. Given that most controlled trials of 
antipsychotic drugs last on average 3 months it is interesting to read in this study that a large 
proportion of behavioural incidents lasted less than 3 months. In this study, 53% of the patients 
not taking antipsychotics experienced resolution of their psychotic symptoms and no significant 
differences in resolution rates were found between the different types of dementia (Ballard et al., 
1997).
Although the elderly constitute 14% of the United States population, they are prescribed 
over one-third of all prescription medications. Nursing home patients are prescribed on average 8 
medications. Unfortunately, adverse drug events are not always recognized as such and are 
consequently treated as a new medical condition resulting in a prescribing cascade that further 
increases the risk of adverse drug reactions. There is also a problem of inappropriate drug use in 
the elderly. Up to 40% of nursing home residents in the United States were prescribed an 
inappropriate drug. In the medicare registrants of Quebec, 56% of 63 268 elderly were found to 
have a high risk prescribing issue such as; the use of questionable drug combination, excessive 
treatment duration and the use of contraindicated medications for the use in the elderly (Shelton, 
Fritsch & Scott, 2000).
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Purpose o f the Study
The purpose of this study is to examine the frequencies and the structure of scores on 
MDS (2.0) items relevant to disruptive behaviour and antipsychotic medications in elderly 
residents in LTC homes. Two previous RAI studies found that disruptive behaviour was 
predicted in regression analysis by several MDS items including antipsychotic medications, 
bladder incontinence, depression, delirium, restraint use and Activities of daily living or ADLs 
(Stewart, 2005; Stones et al., 2003). Limitations of these studies included (a) failure to account 
for relationships among the predictor variables and (b) failure to account for an anticipated 
bidirectional relationship between disruptive behaviour and the use of antipsychotics.
Anticipation of a bidirectional relationship between disruptive behaviour and 
antipsychotic use occurs because high levels of disrupted behaviour are a reason to prescribe 
antipsychotics whereas the postulated effects of the latter include a lowering of disruptive 
behaviour. Consequently, any regression of antipsychotic use (as predictor variable) on 
disruptive behaviour (as predicted variable) provides a regression coefficient that confounds 
positive and negative trends. The present study attempted to disentangle this confound by using 
LISREL path analysis to test the hypothesized bidirectional relationship of negative 
antipsychotic on disruptive behaviour and positive disruptive behaviour on antipsychotic trends.
Other predictors of disruptive behaviour specified in the LISREL model derived from 
reviews of the literature by Stewart (2005) and Stone, Stewart & Kirkpatrick (2003). The direct 
predictors of disruptive behaviour included delirium, depression, and bladder incontinence all of 
which are sources of distress or discomfort. Other continuous measures reported in the literature 
as correlates of disruptive behaviour included cognitive impairment, activities of daily living, 
and physical restraint. The model specified the following positive effects among these measures:
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cognitive impairment on delirium and physical restraint, delirium on physical restraint and 
depression, and impaired activities of daily living on physical restraint (i.e., because the latter’s 
use in the context of safety of physically impaired residents). Finally, the model specified a 
negative effect of impaired activities of daily living on antipsychotic use because of termination 
of the latter at the highest levels of activities of daily living impairment.
Variables cited in the literature as correlates of disruptive behaviour but not included in 
the LISREL analysis included measures that violate assumptions of continuity required by the 
model (e.g., noncontinuous measures such as diagnostic category).
Method
Participants
Participants included 1479 frail elderly and disabled adults residing in LTC facilities in 
Ontario during 2000. Data were collected as part of an Ontario-wide Resident Assessment 
Instrument Health Infomatics Project (RAIHIP). Although data collection was below census 
level except in a minority of long-term care homes, it remains the largest and most carefully 
collected data base in the province to date.
Material
The Minimum Data Set 2.0 (MDS 2.0) from 2000 was the key data source. The MDS 2.0 
is the main functional assessment of the Resident Assessment Instrument (RAI). It includes 
several domains such as activities of daily living (ADLs), nutrition, continence, behaviour and 
cognition. The RAI is a tool that provides a comprehensive assessment of the individual patient.
It is designed to monitor the individual status and progress of the medical, psychological and 
social characteristics of residents within care facilities. It has demonstrated a good interrater 
reliability (Shelton et al., 2000). The assessment is administered upon admission into a facility
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and in quarterly assessments thereafter by trained nursing staff. Findings support the reliability 
and clinical utility of the MDS 2.0 (Morris et a l, 1997).
Dependent Variables
The dependent variables (DV) included in the model consisted of the Disruptive 
Behaviour Scale, antipsychotic use, delirium and restraint use. The MDS Disruptive Behaviour 
Scale (Stones et al., 2003) includes the behavioural symptoms on the MDS (2.0). The items 
include verbally abusive behaviour by residents, physically abusive behaviour by residents, 
socially inappropriate behaviour and resistance to care. These items measure the frequency of the 
resident’s behaviour within the last 7 days. Scores are based on a 4-point scale, where 0 means 
behaviour not present, 1 means behaviour was present 1-3 days, 2 means behaviour occurred in 
4-6 days, and 3 means behaviour occurred daily. The items also measure the alterability of the 
behaviour in the last 7 days. These items are scored on a 2-point scale, such that, 0, means 
residents ’ behaviour was easily altered or not present and 1 means behaviour was not easily 
altered. The scoring on the Disruptive Behaviour Scale is the sum of each of the frequency and 
alterability of resident’s behaviour. Scores can range from 0 to 16. Internal consistency estimates 
of reliability for this scale determined that the scale has good reliability (coefficient alpha =
.835).
Antipsychotic use was coded according to 0 = not received in the last 7 days and number 
o f days (1 to 7) if it was received in the last 7 days. Long acting medications are included even if 
used less than weekly.
Delirium was coded as the behaviour being present in the last 7 days in that 0 = 
Behaviour not present, 1 = Behaviour present, not o f  recent onset, 2 -  Behaviour present, over 
last 7 days appears different from resident’s usual functioning (e.g., new onset or worsening). It
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included whether the resident was easily distracted (e.g., difficulty paying attention, gets 
sidetracked); if the resident had periods of altered perception or awareness of surroundings (e.g., 
moves lips or talks to someone not present; believes he or she is somewhere else; confuse night 
and day); episodes of disorganized speech (e.g., speech is incoherent, nonsensical, irrelevant, or 
rambling from subject to subject; loses train of thought); periods of restlessness (e.g., fidgeting 
or picking at skin, clothing, napkins, etc.; frequent position changes, repetitive physical 
movements or calling out); periods of lethargy (e.g., sluggishness, staring into space, difficult to 
arouse, little bodily movement) and whether mental function varied over the course of the day 
(e.g., sometimes better, sometimes worse; behaviours sometimes present, sometimes not).
Restraints was coded according to their use in the last 7 days whereas 0 = Not used, 1 = 
Used less than daily and 2 = Used daily. They include trunk restraint. Limb restraint and chair 
that prevents rising. Residents are assessed by direct observation and in consultation with other 
staff members and records.
Predictors
The independent variables (IV) included ADL self-performance and support. Depression 
Rating Scale, Cognitive Performance Scale and bladder incontinence.
Activities o f  daily living (ADL) refer to the residents’ self-performance on the MDS (2.0) 
in the last 7 days. Physical functioning and structural problems include ADL self-performance 
and support provided. Self-performance was rated on a 6 point scale where 0 = Independent, 1 = 
supervision, 2 = limited assistance, 3 = extensive assistance, 4 = total dependence, and 8 = 
activity did not occur. Support provided was rated on a 5-point scale where no help from
staff, 1 = set up help only, 2 = one person assist, 3 = 2 or more person assist, and 8 = activity did 
not occur.
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Depressed affect is coded for indicators observed in the last 30 days, irrespective of the 
assumed cause. Indicators include verbal expression of distress, sleep-cycle issues, sad, apathetic 
or anxious appearance and loss of interest. Residents are scored on a 3-point scale where 0 = 
indicator not exhibited in last 30 days, 1 = indicator o f this type exhibited up to 5 days a week, 
and 2 = indicator o f this type exhibited daily or almost daily (6, 7 days).
Cognitive impairment includes a resident’s short term and long term memory, and 
assesses whether the resident has memory problems. It also assesses recall abilities such as 
current season, location of their own room, staff names and faces, whether one knows they are in 
a facility or none recalled. Decision making abilities are assessed on a four-point scale where 0 = 
independent, 1 = modified independence, 2 = moderately impaired and 3 = severely impaired.
Bladder incontinence is measured in the last 14 days regardless of continence programs 
or appliances (e.g., Foley). Urinary continence performance is coded as 0 = complete control, 1 
= usually continent, 2 = occasionally incontinent, 3 = frequently incontinent, 4 = Incontinent,
Results
Distribution o f Variables
Results indicated that out of 1479 residents, 44% displayed some disturbing behaviour 
and that overall 25% of the residents used an antipsychotic medication in the last 7 days. It was 
also found that 75% of residents had bladder incontinence. Depressive symptoms were exhibited 
by 63% of the residents and 86% had some degree of cognitive impairment. Results also showed 
that a mere 0.9% of residents were physically restrained on a daily basis. Delirium or disordered 
thinking was displayed by 68% of the residents in the last 7 days.
Scores on the Disruptive Behaviour Scale determined that 830 residents (56%) displayed 
no disruptive behaviour while 649 (44%) showed varying degrees of disruptive behaviour {M=
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1.69, SD = 2.53). Scores on the Disruptive Behaviour Scale range from 0 to 10 (see Figure 1).
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Disruptive Behaviour
Figure 1. Frequency of disruptive behaviour ranging from none (0) to some (1 to 10).
Scores on the antipsychotic scale determined that upon admissionll09 residents (75%) did 
not use an antipsychotic medication in the last 7 days. Whereas, 370 (25%) residents used an 









Figure 2. Antipsychotic use, 0 (not used), 1 to 7 (used in the last week).
Scores on the activities of daily living (ADL) assessment indicate a {M = 9 2 \, SD = 
5.30). Scores can range from 0 to 8 in two categories. The first category includes a self­
performance score where 0 means resident is independent, 1 = needs supervision, 2 = limited 
assistance, 3 = extensive assistance, 4 = total dependence, and 8 = activity did not occur. The 
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Activities of Daiiy Living
Figure 3. Activities of daily living.
Scores on the continence scale indicate that 365 (25%) residents had complete bladder 








Figure 4. Indicates bladder continence in the last 14 days, 0 = continent, 1-4 -  incontinent.
Scores on the Depression scale ranged from 0 to 14. Results indicate that 549 (37%) did not 
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D epression
Figure 5. Depressive symptoms 0 = not exhibited, 1-14 -  exhibited.
Cognitive Impairment with a minimum score of 0 and a maximum score of 6. Results 
indicate that 204 (14%) residents had no memory impairment while 1275 (86%) residents had 




Figure 6. Cognitive patterns, 0 = no memory impairment, 1-6 = memory impairment
Restraint use found that in 1076 (73%) of the cases in was not used, in 389 (26%) of the 








R estraint u se
Figure 7. Restraint use, 0 = not used, 1 = used less than daily and 2 = used daily.
Delirium score ranged from 0 to 6. It was found that 471 (32%) did not display the 
behaviour and that 1471(68%) displayed some type of disorganized thinking or delirium (A/ = 










Figure 8. Delirium-periodic disordered thinking/awareness.
Correlations
The correlation matrix in Table 1 shows relationships (- or +) between the variables. 
Results indicate that disruptive behaviour was positively correlated with all the variables 
meaning that as disruptive behaviours increase so does everything else such as more 
antipsychotic use, more ADL assistance, more bladder incontinence, more depressive symptoms, 
more cognitive impairment, more restraint use, and more delirium.
Those who received an antipsychotic medication were more likely to display disruptive 
behaviour, to suffer from depression, to be cognitively impaired and to suffer from delirium. 
They were also more likely to require less assistance with ADL.
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A higher level of assistance with ADL was associated with a greater display o f disruptive 
behaviour, bladder incontinence, cognitive impairment, restraint use and delirium and again 
those with greater ADL needs received less antipsychotic medications. Those displaying more 
bladder incontinence were also more disruptive, required more assistance with ADLs, had 
greater cognitive impairment, were most often restrained and suffered more delirium.
Residents who displayed a greater amount of depressive symptoms were more likely to 
be disruptive, receive an antipsychotic medication and suffer from delirium. They were however 
less often restrained.
Those with greater cognitive impairment were most often disruptive, given antipsychotic 
medications, required more assistance with ADLs, were more likely bladder incontinent, were 
most often restrained, and suffered more delirium. Restraint use was associated with greater 
disruptive behaviour, bladder incontinence, cognitive impairment, delirium and more assistance 
needed with ADLs. Restraint use however was associated with lower levels of depressive 
symptoms.
As with disruptive behaviour, delirium was positively correlated with all of the variables. 
As delirium increases so does disruptive behaviour, antipsychotic medications use, ADL needs, 
bladder incontinence, depression, cognitive impairment and restraint use. It is interesting to note 
the relationship between antipsychotic medications and ADL. According to these results, the 
more independent residents are with ADL the more antipsychotic medications they receive. This 
relationship between ADLs and antipsychotic medications was also found in Lovheim et al.
(2006). These authors concluded that the level of threat perceived by the staff was related to 
whether or not one received an antipsychotic.
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Table 1
Correlation Matrix With the Predictors and Dependent Variables




Bladderlnc .164** -.026 .620**
Depression .327** .151** .014 -.013
Cognitimp .273** .114** .597** .410** -.043
Restraint .121** .007 .503** .311** -.057* .394**
Delirium .384** .219** .359** .264** .208** .591** .262**
** correlation is significant at the 0.01 level
* correlation is significant at the 0.05 level
Path Analysis
A form of Structural Equation Modeling (SEM) called Path Analysis used the LISREL 
computer program. There are several advantages for the use of SEM. The relationships 
among variables have measurement error removed through estimation providing more accurate 
common variance. Reliability of measurement can be accounted for explicitly within the analysis 
by examining and removing the measurement error. SEM is the only analysis that allows 
complete and simultaneous tests of all the relationships (Tabachnick & Fidell, 2001).
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The Hypothesized Model
A path analysis on MDS data, was performed through Lisrel on eight variables found to 
be of significance in previous research (Stones et al., 2003). The hypothesized model is depicted 
in Figure 8. The observed variables are represented by rectangles. The relationships between the 
variables are indicated by lines; the absence of a line implies that no direct relationship has been 
hypothesized. A line with one arrow represents a hypothesized direct relationship between two 
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Figure 9: Path diagram o f  the hypothesized model
Figure 9: Path diagram of the hypothesized model.
Assumptions




The analyzed data set consisted of the covariance matrix (see Table 2).
Table 2
Covariance Matrix Analysed Using LISREL Path Analysis
Disrupt Antipsych Delirium Restraint ADL Depress ion Cognimp Bladdinc
Disrupt 6.419
Antipsych 1.957 8.781
Delirium 1.996 1.333 4.211
Restraint .144 .010 .253 .222
ADL 2.302 -.815 3.910 1.255 28.114
Depression 2.010 1.084 1.034 -.065 .184 5.881
Cognimp 1.402 .681 2.455 .376 6.413 -.212 4.101
Bladdinc .707 -0.131 422 .249 5.599 -.055 1.414 2.902
Results of the initial hypothesized model are indicated in Table 3.
Table 3
Lisrel Estimates and Significant t Values
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Maximum likelihood estimation was employed to estimate the model. The hypothesized 
model was tested and support was foimd, %2 (10, A =  1479) = 42.16 (P = .000), Goodness of fit 
Index (GFI) = .993, Adjusted (GFI) = .975. Post hoc model modifications were performed in 
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Figure 10: Path diagram o f  the final model
Figure 10. Path diagram of the hypothesized final model.
A path predicting disruptive behaviour from delirium was added and is now represented 
by two arrows which indicate a bidirectional relationship. Results from the chi-square difference 
test indicated that the model was significantly improved by this addition yl{\,N==  1479) =
21.034 p < .01. The model was re-estimated and found to be a good fit %2 (9, N -  1479) = 21.08, 
p  < .01, GFI = .996, AGFI = .986.
Table 4 depicts (in order of importance) the Lisrel estimates and t values for the final
model.
Table 4
Lisrel Estimates and Significant t Values
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Predictor Predicted Parameter estimates t values
Delirium —> Disruptive behaviour .644 11.686
Cognitive impairment —> Delirium .642 24.195
Disruptive behaviour —> Antipsychotic .541 8.853
Depression —> Disruptive behaviour .269 9.249
Depression —> Delirium .252 11.465
Restraint use —> Delirium .226 2.218
Antipsychotic —> Disruptive behaviour -.215 -4.604
Cognitive impairment —̂ Antipsychotic .149 3.008
Disruptive behaviour —> Delirium -.148 -4.239
ADLs —> Antipsychotic -.107 -6.013
ADLs —> Restraint use .037 14.948
Cognitive impairment Restraint use .034 5.250
Results indicate that the path between bladder incontinence and disruptive behaviour is 
no longer significant. The added path between disruptive behaviour and delirium is significant 
and suggest that being disruptive might be adaptive in lowering delirium.
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Discussion
All paths hypothesized to have a positive or negative effect were confirmed. The only 
unexpected finding was the negative effect of disruptive behaviour on delirium. As we can see in 
this model, the issue of disturbing behaviour and antipsychotic medications in the elderly is a 
complex one. Many variables play a role in disruptive behaviour. Although the path between 
bladder incontinence and disruptive was no longer significant upon improvement of the model, a 
positive correlation still exists. As was suggested in the literature review, unmet needs has been 
found to relate to disruptive behaviour. Thus staff ratios are very important in insuring that basic 
needs are met in a timely fashion. Increases in depressive symptoms were also found to have a 
positive effect on disruptive behaviour. Thus any effort aimed at reducing depressive symptoms 
in LTC residents should help reduce disruptive behaviour. As was mentioned in the literature 
review, efforts at reducing some of the causes of delirium such as medication intoxication, 
dehydration and infection should also impact disruptive behaviour since delirium and disruptive 
behaviour often co-occur.
A surprising and somewhat interesting finding was the negative effect found between 
disruptive behaviour and delirium. Reasons as to why disruptive behaviours reduce symptoms of 
delirium raises more questions than answers. For example: Does severity of delirium play a role 
in disruptive behaviour? If so, how much of a role does it play? Do all patients who become 
delirious end up being disruptive? If not, is there a difference between delirious individuals who 
display disruptive behaviour and those who do not? More research on this relationship is needed.
A strength of this study consisted of the statistical test employed. Lisrel Path Analysis 
allowed for several MDS 2.0 items, previously found to relate to disruptive behaviour, to be 
analyzed simultaneously. This allowed for a clearer picture to emerge because it took into
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consideration the relationship among the variables and the bidirectional relationship between 
antipsychotic medications and disruptive behaviour and the bidirectional relationship between 
delirium and disruptive behaviour. Another strength of this study consisted of the large database 
provided by the MDS 2.0.
Limitations however included the year of the data. More recent data could have provided a 
different picture of the situation. Also, this dataset did not provide precisions with regards to 
antipsychotic medications. For example it did not indicate the type of antipsychotic (typical of 
atypical), the amount of time residents were receiving the antipsychotics, the dosage, or any side 
effects that might have been experienced as a result of the antipsychotics. The only information 
it provided is whether residents had received an antipsychotic medication in the last seven days 
or not. Another limitation was that this dataset did not specify the type of disturbing behaviour 
that warranted an antipsychotic medication. For example was the antipsychotic given for reasons 
of aggression or restlessness?
This study has raised some important issues with regards to the care and research of elderly 
residents in LTC. Although antipsychotics do have a negative effect on disruptive behaviour, 
they should be prescribed wisely. Non-pharmacological interventions could help address many 
of the variables included in the model and should be implemented.
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